Novartis inks $1B protein degrader deal with Arvinas, begins MorphoSys tender offer
Novartis announced Thursday an exclusive strategic partnership with Arvinas to advance an oral protein degrader for prostate cancer, while also announcing the tender offer for its $2.9 billion acquisition of MorphoSys has commenced.